Amazon launches six-month $6 prescriptions to Prime members

The new benefit program follows Walmart's announcement and seeks to disrupt the prescription drug market.

| More on:
woman chatting online on her macbook

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Amazon (NASDAQ: AMZN) announced today that it is launching a new prescription program for members of its Prime loyalty program, less than a day after Walmart (NYSE: WMT) said it was offering Walmart+ members a discounted prescription service as well.

Having acquired PillPack in 2018, Amazon has been looking to leverage its ability to buy prescription medicine in bulk and provide savings to members in a bid to take a large slice of the $360 billion prescription drug market.

Like the Walmart program, Amazon's new service is looking for patients who take just a small number of fairly common medicines, such as those used to treat high blood pressure and diabetes; they'll pay as little as $1 per month and receive a six-month supply.

Six months is typically longer than what insurance companies will pay for, so consumers could see real savings by enrolling in the healthcare prescription program. As Prime members, they'd also be entitled to receive free two-day delivery.

The new offer is an expansion of the Amazon Pharmacy benefit announced last month that allows Prime members to comparison shop for savings through its network of 60,000 pharmacies. It noted Prime members save 80% on generic medications and 40% on name-brand ones through Amazon Pharmacy.

Walmart just introduced Walmart+ RX, which also provides significant discounts on commonly used medications. It notes that members of Walmart+, a loyalty program the retailer launched to challenge Amazon Prime, can get some common medications free while saving up to 85% on others.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Rich Duprey has no position in any of the stocks mentioned. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Amazon. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. The Motley Fool Australia has recommended Amazon. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

International Stock News

Mark Zuckerberg just delivered incredible news for Nvidia stock investors

What did Meta Platforms CEO Mark Zuckerberg say and what does it mean for AI stocks like Nvidia?

Read more »

Happy woman on her phone while her electric vehicle charges.
International Stock News

Better EV stock: Rivian vs. Tesla

Tesla is the leader in EVs, but its fourth-quarter results were unimpressive. Rivian is a speculative EV stock, but the…

Read more »

a man sits at his computer screen with a cup of coffee in one hand and the other shielding the bottom half of his face with his eyes closed although he is recoiling from bad news.
International Stock News

Why Alphabet stock just slumped 7%

Alphabet reported mixed results in its fourth-quarter financial report.

Read more »

a tired and sad looking bulldog sits at an office desk with a pen an paper on it and a cup of coffee with his head resting on the desk as he gives a mournful look to the camera.
International Stock News

These were the 5 worst-performing stocks in the Nasdaq-100 in January 2025

Although most stocks made forward progress in January, a few of them bucked the bigger trend for understandable reasons.

Read more »

Man pointing at a blue rising share price graph.
International Stock News

Why Nvidia stock just surged

The good news continues to pour in for the artificial intelligence (AI) chipmaker.

Read more »

A man pointing a remote towards a TV whilst covering his eyes
International Stock News

Every Nvidia investor should keep an eye on this number

There's one number to watch when Nvidia reports its fiscal 2025 fourth-quarter earnings on February 26.

Read more »

Woman has a confused expression as she looks at phone.
International Stock News

Is Nvidia stock a buy right now?

Nvidia's business remains strong, as illustrated by 94% year-over-year sales growth in its fiscal third quarter.

Read more »

A boy with question mark on his forehead looking up as if watching an ASX share price
International Stock News

Should you buy Nvidia shares before Febuary 26? The evidence is piling up, and here's what it says

Nvidia’s next potential catalyst is just a couple of weeks away.

Read more »